Abstract

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.

Keywords

Chimeric antigen receptorLymphomaAdoptive immunotherapyImmunotherapyAdoptive cell transferMedicineLeukemiaImmunologyCancer researchCancerCancer immunotherapyT cellOncologyInternal medicineImmune system

MeSH Terms

Cell EngineeringCell- and Tissue-Based TherapyClinical Trials as TopicGenetic EngineeringHumansImmunotherapyAdoptiveMutant Chimeric ProteinsNeoplasmsReceptorsAntigenT-CellT-Lymphocytes

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
review
Volume
359
Issue
6382
Pages
1361-1365
Citations
2861
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2861
OpenAlex
64
Influential
2585
CrossRef

Cite This

Carl H. June, Roddy S. O’Connor, Omkar U. Kawalekar et al. (2018). CAR T cell immunotherapy for human cancer. Science , 359 (6382) , 1361-1365. https://doi.org/10.1126/science.aar6711

Identifiers

DOI
10.1126/science.aar6711
PMID
29567707

Data Quality

Data completeness: 90%